scholarly journals Antiobesity effect of Pediococcus pentosaceus LP28 on overweight subjects: a randomized, double-blind, placebo-controlled clinical trial

2016 ◽  
Vol 70 (5) ◽  
pp. 582-587 ◽  
Author(s):  
F Higashikawa ◽  
M Noda ◽  
T Awaya ◽  
N Danshiitsoodol ◽  
Y Matoba ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Pediococcus Pentosaceus ◽  
Double Blind Placebo ◽  
Overweight Subjects

Effect of the cumin cyminum L. Intake on Weight Loss, Metabolic Profiles and Biomarkers of Oxidative Stress in Overweight Subjects: A Randomized Double-Blind Placebo-Controlled Clinical Trial

2015 ◽  
Vol 66 (2-3) ◽  
pp. 117-124 ◽  
Author(s):  
Mohsen Taghizadeh ◽  
Mohammad Reza Memarzadeh ◽  
Zatollah Asemi ◽  
Ahmad Esmaillzadeh
Keyword(s):  
Clinical Trial ◽  
Weight Loss ◽  
Serum Insulin ◽  
Controlled Clinical Trial ◽  
Metabolic Profiles ◽  
Double Blind ◽  
Insulin Metabolism ◽  
Double Blind Placebo ◽  
Cuminum Cyminum ◽  
Overweight Subjects

Background: The current study was performed to determine the effects of cumin cyminum L. intake on weight loss and metabolic profiles among overweight subjects. Methods: This randomized double-blind placebo-controlled clinical trial was conducted among 78 overweight subjects (male, n = 18; female, n = 60) aged 18-60 years old. Participants were randomly assigned into three groups to receive: (1) cumin cyminum L. capsule (n = 26); (2) orlistat120 capsule (n = 26) and (3) placebo (n = 26) three times a day for 8 weeks. Anthropometric measures and fasting blood samples were taken at baseline and after 8 weeks of intervention. Results: Consumption of the Cuminum cyminum L. and orlistat120 resulted in a similar significant decrease in weight (-1.1 ± 1.2 and -0.9 ± 1.5 vs. 0.2 ± 1.5 kg, respectively, p = 0.002) and BMI (-0.4 ± 0.5 and -0.4 ± 0.6 vs. 0.1 ± 0.6 kg/m2, respectively, p = 0.003) compared with placebo. In addition, taking Cuminum cyminum L., compared with orlistat and placebo, led to a significant reduction in serum insulin levels (-1.4 ± 4.5 vs. 1.3 ± 3.3 and 0.3 ± 2.2 µIU/ml, respectively, p = 0.02), HOMA-B (-5.4 ± 18.9 vs. 5.8 ± 13.3 and 1.0 ± 11.0, respectively, p = 0.02) and a significant rise in QUICKI (0.01 ± 0.01 vs. -0.005 ± 0.01 and -0.004 ± 0.01, respectively, p = 0.02). Conclusion: Taking cumin cyminum L. for eight weeks among overweight subjects had the same effects of orlistat120 on weight and BMI and beneficial effects on insulin metabolism compared with orlistat120 and placebo.

Double blind placebo controlled clinical trial of homoeopathic medicines in HIV infection

1998 ◽  
Vol 87 (2) ◽  
pp. 86-88
Author(s):  
D P Rastogi ◽  
V P Singh ◽  
Vikram Singh ◽  
S K Dey ◽  
K Rao
Keyword(s):  
Clinical Trial ◽  
Hiv Infection ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo

Significant immunomodulatory and hepatoprotective impacts of Silymarin in MS patients: A double-blind placebo-controlled clinical trial

2021 ◽  
Vol 97 ◽  
pp. 107715
Author(s):  
Faezeh Abbasirad ◽  
Vahid Shaygannejad ◽  
Fahimeh Hosseininasab ◽  
Omid Mirmosayyeb ◽  
Behzad Mahaki ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo

Effects of creatine supplementation on renal function: a randomized, double-blind, placebo-controlled clinical trial

2008 ◽  
Vol 103 (1) ◽  
pp. 33-40 ◽  
Author(s):  
Bruno Gualano ◽  
Carlos Ugrinowitsch ◽  
Rafael Batista Novaes ◽  
Guilherme Gianini Artioli ◽  
Maria Heloisa Shimizu ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Renal Function ◽  
Creatine Supplementation ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document